The hallucinogenic herb Salvia divinorum and its active ingredient salvinorin A reduce inflammation-induced hypermotility in mice

Neurogastroenterology and Motility

Volumn 20, Issue 2, 2008, Pages 142-148

  Capasso, R ^a   Borrelli, F ^a   Zjawiony, J ^b,c   Kutrzeba, L ^b   Aviello, G ^a   Sarnelli, G ^a   Capasso, F ^a   Izzo, A A ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

opioid receptors; Inflammation; Intestinal motility; Myenteric plexus; Salvinorin A

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; CROTON OIL; HERBACEOUS AGENT; NALOXONE; NORBINALTORPHIMINE; PLANT EXTRACT; SALVIA DIVINORUM EXTRACT; SALVINORIN A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG ISOLATION; ENTERITIS; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRANSIT; MALE; MOUSE; NONHUMAN; PLANT LEAF; PRIORITY JOURNAL;

3,4-DICHLORO-N-METHYL-N-(2-(1-PYRROLIDINYL)-CYCLOHEXYL)-BENZENEACETAMIDE, (TRANS)-ISOMER; ANALGESICS, NON-NARCOTIC; ANIMALS; DITERPENES; GASTROINTESTINAL MOTILITY; HALLUCINOGENS; INFLAMMATION; MALE; MICE; MICE, INBRED ICR; PLANT EXTRACTS; PLANT LEAVES; RECEPTORS, OPIOID, KAPPA; SALVIA;

EID: 38149069125     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2007.00994.x     Document Type: Article

References (24)

1. Valdes LJ III., Hatfield GM, Koreeda M, Paul AG. Studies of Salvia divinorum (Lamiaceae), an hallucinogenic mint from the Sierra Mazateca in Oaxaca, Central Mexico. Econ Bot 1987 41 : 283 91.
2. Siebert DJ. Localization of salvinorin A and related compounds in glandular trichomes of the psychoactive sage, Salvia divinorum. Ann Bot 2004 93 : 763 71.
3. Valdes LJ III., Diaz JL, Paul AG. Ethnopharmacology of ska Maria Pastora (Salvia divinorum, Epling and Jativa-M.). J Ethnopharmacol 1983 7 : 287 312.
4. Vortherms TA, Roth BL. Salvinorin A: from natural product to human therapeutics. Mol Interv 2006 6 : 257 65.
5. Siebert DJ. Salvia divinorum and salvinorin A: new pharmacologic findings. J Ethnopharmacol 1994 43 : 53 6.
6. Sheffler DJ, Roth BL. Salvinorin A: the "magic mint" hallucinogen finds a molecular target in the kappa opioid receptor. Trends Pharmacol Sci 2003 24 : 107 9.
7. Roth BL, Baner K, Westkaemper R et al. Salvinorin A: a potent naturally occurring non-nitrogenous kappa opioid selective agonist. Proc Natl Acad Sci U S A 2002 99 : 11934 9.
8. Chavkin C, Sud S, Jin W et al. Salvinorin A, an active component of the hallucinogenic sage Salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations. J Pharmacol Exp Ther 2004 308 : 1197 203.
9. Nichols DE. Hallucinogens. Pharmacol Ther 2004 101 : 131 81.
10. Sternini C, Patierno S, Selmer IS, Kirchgessner A. The opioid system in the gastrointestinal tract. Neurogastroenterol Motil 2004 16 (Suppl 2 3 16.
11. Waterman SA, Costa M, Tonini M. Modulation of peristalsis in the guinea-pig isolated small intestine by exogenous and endogenous opioids. Br J Pharmacol 1992 106 : 1004 10.
12. Shahbazian A, Heinemann A, Schmidhammer H, Beubler E, Holzer-Petsche U, Holzer P. Involvement of mu- and kappa-, but not delta- opioid receptors in the peristaltic motor depression caused by endogenous and exogenous opioids in the guinea-pig intestine. Br J Pharmacol 2002 135 : 741 50.
13. Cherubini E, Morita K, North RA. Opioid inhibition of synaptic transmission in the guinea-pig myenteric plexus. Br J Pharmacol 1985 85 : 805 17.
14. Joshi SK, Su X, Porreca F, Gebhart GF. Kappa-opioid receptor agonists modulate visceral nociception at a novel, peripheral site of action. J Neurosci 2000 20 : 5874 9.
15. Capasso R, Borrelli F, Capasso F et al. The hallucinogenic herb Salvia divinorum and its active ingredient salvinorin A inhibit enteric cholinergic transmission in the guinea-pig ileum. Neurogastroenterol Motil 2006 18 : 69 75.
16. Puig MM, Pol O. Peripheral effects of opioids in a model of chronic intestinal inflammation in mice. J Pharmacol Exp Ther 1998 287 : 1068 75.
17. Capasso R, Izzo AA, Fezza F et al. Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice. Br J Pharmacol 2001 134 : 945 50.
18. Capasso R, Matia I, Lutz B et al. Fatty acid amide hydrolase controls mouse intestinal motility in vivo. Gastroenterology 2005 129 : 941 51.
19. Halpern JH. Hallucinogens: an update. Curr Psychiatry Rep 2003 5 : 347 54.
20. Nomura Y, Hayashi S. Pre- and post-synaptic effects of spiradoline and U-50488H, selective kappa opioid receptor agonists, in isolated ileum. Scand J Gastroenterol 1992 27 : 295 302.
21. Bansinath M, Ramabadran K, Turndorf H, Puig MM. Kappa-opiate agonist-induced inhibition of gastrointestinal transit in different strains of mice. Pharmacology 1991 42 : 97 102.
22. Hayes AG, Tyers MB. Determination of receptors that mediate opiate side effects in the mouse. Br J Pharmacol 1983 79 : 731 6.
23. Shook JE, Lemcke PK, Gehrig CA, Hruby VJ, Burks TF. Antidiarrheal properties of supraspinal mu and delta and peripheral mu, delta and kappa opioid receptors: inhibition of diarrhea without constipation. J Pharmacol Exp Ther 1989 249 : 83 90.
24. Pol O, Puig MM. Expression of opioid receptors during peripheral inflammation. Curr Top Med Chem 2004 4 : 51 61.